Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Hold” by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given an average recommendation of “Hold” by the seven research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $4.50.

Several equities research analysts have weighed in on FULC shares. Cantor Fitzgerald raised Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 price objective on the stock in a research note on Thursday, May 15th. HC Wainwright reiterated a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th.

Fulcrum Therapeutics Stock Down 6.1%

Fulcrum Therapeutics stock opened at $6.51 on Wednesday. The company has a market cap of $351.40 million, a price-to-earnings ratio of -21.00 and a beta of 2.29. The firm’s fifty day moving average is $3.84 and its 200 day moving average is $3.85. Fulcrum Therapeutics has a 52-week low of $2.32 and a 52-week high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. On average, equities research analysts anticipate that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Algert Global LLC lifted its stake in Fulcrum Therapeutics by 6.0% in the first quarter. Algert Global LLC now owns 36,147 shares of the company’s stock worth $104,000 after purchasing an additional 2,030 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Fulcrum Therapeutics by 2.6% during the 1st quarter. American Century Companies Inc. now owns 123,711 shares of the company’s stock worth $356,000 after acquiring an additional 3,100 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Fulcrum Therapeutics by 2.3% during the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock worth $667,000 after purchasing an additional 3,126 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Fulcrum Therapeutics in the 4th quarter worth about $38,000. Finally, Brooklyn Investment Group increased its position in shares of Fulcrum Therapeutics by 209.7% during the first quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock worth $35,000 after acquiring an additional 8,254 shares during the period. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.